Presentation is loading. Please wait.

Presentation is loading. Please wait.

Advances in HIV Care.

Published byAbraham Strickland Modified over 6 years ago

Similar presentations

Presentation on theme: "Advances in HIV Care."— Presentation transcript:

1 Advances in HIV Care

2

3

4 Prevention of HIV Infection in Women

5 ASPIRE Dapivirine Ring

6 ASPIRE (cont) Dapivirine Ring

7 Ring Study Dapivirine Vaginal Ring for HIV-1 Prevention in African Women

8 Ring Study (cont) Dapivirine Vaginal Ring for HIV-1 Prevention in African Women

9 Vaginal Ring for Delivery of ART for HIV-1 Prevention in Women Is the Glass Half Full or Half Empty?

10 Good News, Bad News

11 ÉCLAIR Cabotegravir LA in HIV-Uninfected Men

12 ÉCLAIR (cont) Cabotegravir LA in HIV-Uninfected Men

13 ÉCLAIR Cabotegravir LA for Prevention of in HIV-Uninfected Men: Safety

14 ÉCLAIR Cabotegravir LA for Prevention of in HIV-Uninfected Men: PK

15 LATTE-2: Week 32 Results Cabotegravir (INSTI) + Rilpivirine (NNRTI) As LA Maintenance Therapy

16 LATTE-2: Week 32 Results (cont) Cabotegravir (INSTI) + Rilpivirine (NNRTI) As LA Maintenance Therapy

17 LATTE-2: Week 32 Results (cont) Cabotegravir (INSTI) + Rilpivirine (NNRTI) As LA Maintenance Therapy

18 NNRTIs

19 Doravirine 100mg QD vs Efavirenz + TDF/FTC In ART-Naive HIV+ Patients: Week 48 Results

20 Doravirine 100mg QD vs Efavirenz + TDF/FTC In ART-Naive HIV+ Patients: Week 48 Results (cont)

21 ACTG 5273 (SELECT) Second-Line ART Supports WHO Guidance

22 ACTG 5273 (SELECT) Association of NRTI Resistance at Baseline

23 Long-Term Adherence Challenges

24 A Patient Navigation/Contingency Management RCT for Hospitalized HIV+ Substance Users The Hope Study

25 A Patient Navigation/Contingency Management RCT for Hospitalized HIV+ Substance Users (cont) The Hope Study

26 Efficiency of HIV Target Cell Delivery Following Oral Administration of Tenofovir Prodrugs

27 Switching TDF to TAF Week 48 Results

28 Switching TDF to TAF (cont) Week 48 Results

29 Rapid Accumulation of Defective Proviruses Complicates HIV-1 Reservoir Measurements

30 ART Reduces Cellular HIV RNA But Not the Fraction of Proviruses Transcribing RNA

31 ACTG-5340 Can VRC01 Prevent or Delay the Return of Viremia After Interruption of ART?

32 ACTG-5326 Safety, Immunologic and Virologic Activity of Anti-PD-L1

33 Abbreviations

34 Abbreviations

Download ppt "Advances in HIV Care."

Similar presentations

TMC278 Update, 30th January 2009  C204 data  ECHO and THRIVE - Phase III studies  New TMC278 formulations Peter Williams Tibotec BVBA, Mechelen, Belgium.

TMC278 Update, 30th January 2009  C204 data  ECHO and THRIVE - Phase III studies  New TMC278 formulations Peter Williams Tibotec BVBA, Mechelen, Belgium.
Comparison of INSTI vs PI  FLAMINGO  GS-236-0103  ACTG A5257.

Comparison of INSTI vs PI  FLAMINGO  GS  ACTG A5257.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Phase 2 of new ARVs  Fostemsavir, prodrug of temsavir (attachment inhibitor) –AI438011 Study  TAF (TFV prodrug) –Study 292-0102 –Study 299-0102  Doravirine.

Phase 2 of new ARVs  Fostemsavir, prodrug of temsavir (attachment inhibitor) –AI Study  TAF (TFV prodrug) –Study –Study  Doravirine.
Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*

Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
The Pregnancy Journey Open discussion. HIV and AIDS 2013 Romania Cumulative number people diagnosed with HIV since 1985 19,261 (of which 9,946 diagnosed.

The Pregnancy Journey Open discussion. HIV and AIDS 2013 Romania Cumulative number people diagnosed with HIV since ,261 (of which 9,946 diagnosed.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.

ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.
Switch PI/R to ETR  Etraswitch. Etraswitch Study: Switch PI/r to ETR Continuation of current PI/R + 2 NRTI N = 21 N = 22 ETR 400 mg QD* + 2 NRTI  Design.

Switch PI/R to ETR  Etraswitch. Etraswitch Study: Switch PI/r to ETR Continuation of current PI/R + 2 NRTI N = 21 N = 22 ETR 400 mg QD* + 2 NRTI  Design.
Phase 2 of new ARVs  Fostemsavir, prodrug of temsavir (attachment inhibitor) –AI438011 Study  TAF (TFV prodrug) –Study 292-0102 –Study 299-0102  Doravirine.

Phase 2 of new ARVs  Fostemsavir, prodrug of temsavir (attachment inhibitor) –AI Study  TAF (TFV prodrug) –Study –Study  Doravirine.
Switch to ATV/r monotherapy  ATARITMO  Swedish Study  ACTG A5201  OREY  MODAt Study.

Switch to ATV/r monotherapy  ATARITMO  Swedish Study  ACTG A5201  OREY  MODAt Study.
Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University School of Medicine Medicine Chief of Service Grady Health.

Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University School of Medicine Medicine Chief of Service Grady Health.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.

ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
ID Week Review 2015 Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO October 2015.

ID Week Review 2015 Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO October 2015.
Switch NNRTI to NNRTI  Switch EFV to ETR –CNS toxicity study –Patient’s preference study.

Switch NNRTI to NNRTI  Switch EFV to ETR –CNS toxicity study –Patient’s preference study.
Novel Antiretroviral Studies and Strategies

Novel Antiretroviral Studies and Strategies
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
Coping with Hope 2016 Medical Update

Coping with Hope 2016 Medical Update
Switch to INSTI + NNRTI Switch to DTG + RPV SWORD Study

Switch to INSTI + NNRTI Switch to DTG + RPV SWORD Study

Similar presentations

Ads by Google